Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Arcturus Therapeutics Holdings Inc (ARCT) USD0.001

Sell:$54.11 Buy:$54.32 Change: $1.67 (3.18%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $1.67 (3.18%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $1.67 (3.18%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Arcturus Therapeutics Holdings Inc. is a clinical-stage messenger ribonucleic acid (mRNA) medicines company. The Company is engaged in the development of infectious disease vaccines, and significant opportunities within liver and respiratory rare diseases. The Company offers RNA medicines, RNA drug substance and nanoparticle-formulated drug products. The Company's technologies include Self-Transcribing and Replicating RNA (STARR) and lipid nanoparticle delivery system (LUNAR). The Company has developed the STARR technology platform which combines self-replicating RNA with LUNAR into a single solution. The products under developmental stage using STARR technology are ARCT-021 (LUNAR-COV19 Vaccine), LUNAR-FLU, ARCT-810 (LUNAR - ornithine transcarbamylase (OTC)) and ARCT-032 (LUNAR - cystic fibrosis (CF)). The Company has a pipeline of seven drug candidates in late-stage discovery and early stage development.

Contact details

10628 Science Center Dr Ste 250
United States
+1 (858) 9002660

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.36 billion
Shares in issue:
26.33 million
United States
US dollar

Key personnel

  • Joseph Payne
    President, Chief Executive Officer, Director
  • Andrew Sassine
    Chief Financial Officer, Director
  • Padmanabh Chivukula
    Chief Operating Officer, Chief Scientific Officer
  • Steven Hughes
    Chief Development Officer
  • Lance Kurata
    Chief Legal Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.